Patents Assigned to Glaxo Group Limited
  • Matrix metalloproteinase inhibitors
    Patent number: 8343986
    Abstract: The present invention relates to compounds of Formula (I): pharmaceutically acceptable salts thereof, corresponding preparation processes, pharmaceutical formulations and methods for use as inhibitors of matrix metalloproteinase enzymes (MMPs).
    Type: Grant
    Filed: September 1, 2009
    Date of Patent: January 1, 2013
    Assignee: Glaxo Group Limited
    Inventors: Simon Gaines, Ian Peter Holmes, Stephen Lewis Martin, Stephen Paul Watson
  • Compounds which have activity at Mreceptor and their uses in medicine
    Patent number: 8344000
    Abstract: Compounds of formula (I) and salts thereof are provided: wherein R4, R5, R6, Q, A, and Y are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: January 1, 2013
    Assignee: Glaxo Group Limited
    Inventors: David Gwyn Cooper, Ian Thomson Forbes, Vincenzo Garzya, Dale James Johnson, Paul Adrian Wyman
  • Dry powder medicament formulations
    Patent number: 8337816
    Abstract: A dry powder pharmaceutical composition comprising (i) a medicament particle fraction comprising medicament particles with an aerodynamic diameter no greater than 10 ?m; and (ii) at least 50% of a non-respirable excipient fraction comprising low density excipient particles with an aerodynamic diameter greater than 10 ?m and a geometric diameter greater than 30 ?m. In additional embodiments of the invention, the pharmaceutical composition includes a respirable excipient fraction comprising excipient particles with an aerodynamic diameter no greater than 10 ?m. In a preferred embodiment of the invention, the non-respirable excipient particles include pores adapted to receive a portion of the respirable excipient fraction and/or the medicament fraction.
    Type: Grant
    Filed: September 16, 2002
    Date of Patent: December 25, 2012
    Assignee: Glaxo Group Limited
    Inventors: Andrew Bruce Brown, Michael Mary Van Oort
  • Fault indicator
    Patent number: 8336542
    Abstract: A fault indicator for a strip advancement mechanism comprising a base that defines a fault sensing portion of a path for at least a component of a strip, an element for bearing against a strip, or a component of the strip, while it passes through the fault sensing portion of the path, wherein the element is adapted to move from that bearing or non-fault position, to a fault indicating position in the event of the strip or the component of the strip ceasing to pass through the fault sensing portion of the path.
    Type: Grant
    Filed: May 12, 2006
    Date of Patent: December 25, 2012
    Assignee: Glaxo Group Limited
    Inventors: Gregor John McLennan Anderson, Stephen James Harvey, Andrew Roderick Taylor, Daniel Thomas De Sausmarez Lintell, Mark Digby Teucher, James Anthony West
  • Compounds
    Patent number: 8329730
    Abstract: The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: December 11, 2012
    Assignee: Glaxo Group Limited
    Inventors: Thomas Daniel Heightman, John Skidmore, Hailong Wang, Colin David Eldred, Jag Paul Heer
  • Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists
    Patent number: 8324254
    Abstract: The present invention provides compounds of formula (I) or salts thereof: having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders mediated by S1P1 receptors.
    Type: Grant
    Filed: April 17, 2008
    Date of Patent: December 4, 2012
    Assignee: Glaxo Group Limited
    Inventors: Mahmood Ahmed, Gerard Martin Paul Giblin, James Myatt, David Norton, Dean Andrew Rivers
  • Naphthyridin-2 (1 H)-one compounds useful as antibacterials
    Patent number: 8318940
    Abstract: Compounds of Formula (I), wherein substituents R1, R2 and R5 are as defined, and Ar represents substituted phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, furanyl, imidazolyl and thiophenyl substituted by a hydroxyalkyl substituent and an optional other substituent; compositions containing them, their use in therapy, including their use as antibacterials, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: November 27, 2012
    Assignee: Glaxo Group Limited
    Inventors: Carlos Alemparte-Gallardo, David Barros-Aguirre, Monica Cacho-Izquierdo, Jose Maria Fiandor Roman, Jose Luis Lavandera Diaz, Modesto Jesús Remuiñan-Blanco
  • Benzamide derivatives as EPreceptor agonists
    Patent number: 8314147
    Abstract: A compound of formula (I) or a pharmaceutically acceptable derivative thereof, wherein, R1, R2, R3, R4, R5, m, n and X are as defined in the specification; a process for preparing such compounds; a pharmaceutical composition comprising such compounds; and the use of such compounds in medicine.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: November 20, 2012
    Assignee: Glaxo Group Limited
    Inventors: Alessandra Gaiba, Mark Patrick Healy, Christopher Norbert Johnson, Susan Roomans, Steven James Stanway, Martin Edward Swarbrick
  • NOVEL RETIGABINE COMPOSITION
    Publication number: 20120288544
    Abstract: The present invention relates to an oral dosage form comprising N-(2-amino-4-(fluorobenzylamino)-phenyl)carbamic acid ethyl ester (retigabine) or a pharmaceutically acceptable salt or solvate thereof, to a process for preparing such a dosage form and to the use of such a dosage form in medicine.
    Type: Application
    Filed: January 18, 2011
    Publication date: November 15, 2012
    Applicant: GLAXO GROUP LIMITED
    Inventors: Matthew Burke, Charles Harding Rhodes
  • Muscarinic acetylcholine receptor antagonists
    Patent number: 8309572
    Abstract: Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: November 13, 2012
    Assignee: Glaxo Group Limited
    Inventors: Dramane I. Laine, Michael R. Palovich, Brent W. McCleland, Christopher E. Neipp, Sonia M. Thomas
  • Anhydrous crystal form of ovrepitant maleate
    Patent number: 8309553
    Abstract: The invention relates to anhydrous crystalline orvepitant maleate (Form 1), pharmaceutical formulations comprising the same, its use in therapy and processes for preparing the same, wherein orvepitant is as shown in formula (I).
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: November 13, 2012
    Assignee: Glaxo Group Limited
    Inventors: Stefania Beato, Franco Sartor, Ian Philip Steeples
  • Process for the preparation of 6-?,9-?-difluoro-17-?-((2-furanylcarbonyl)oxy)-11-?-hydroxy-16-?-methy1-3-oxo-androsta-1,4-diene-17-?- -carbothioic acid S-fluoromethyl
    Patent number: 8309713
    Abstract: A novel process for preparing a compound of formula (I) which comprises converting a compound of formula (II) to a compound of formula (I) via a compound of formula (III), or a salt thereof, without isolating any intermediates.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: November 13, 2012
    Assignee: Glaxo Group Limited
    Inventors: Malcolm Brian Berry, Mark Jason Hughes, David Parry-Jones, Stephen John Skittrall
  • Compounds
    Patent number: 8304446
    Abstract: Indazole compounds, processes for their preparation, intermediates usable in these processes, pharmaceutical compositions containing such compounds and their use in therapy.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: November 6, 2012
    Assignee: Glaxo Group Limited
    Inventors: Simon Teanby Hodgson, Yannick Maurice Lacroix, Pauayiotis Alexandron Procopiou
  • Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
    Patent number: 8299291
    Abstract: The present disclosure relates to methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs and to intermediates used in the methods.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: October 30, 2012
    Assignees: XenoPort, Inc., Glaxo Group Limited
    Inventors: Stephen P. Raillard, Suresh K. Manthati, Peng Liu, Qunying Dai, Hao Yin
  • Compounds which have activity at Mreceptor and their uses in medicine
    Patent number: 8299257
    Abstract: Compounds of formula (I) or a salt thereof are provided: wherein R4, R5, R6, Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: October 30, 2012
    Assignee: Glaxo Group Limited
    Inventors: David Gwyn Cooper, Ian Thomson Forbes, Vincenzo Garzya, Dale James Johnson, Graeme Irvine Stevenson, Paul Adrian Wyman
  • Compounds
    Patent number: 8293798
    Abstract: A compound of formula (I) or salts thereof, wherein R1, R2, R3, R4, n and X are as defined in the specification; a process for preparing such compounds, a pharmaceutical composition comprising such compounds; and the use of such compounds in medicine.
    Type: Grant
    Filed: October 30, 2008
    Date of Patent: October 23, 2012
    Assignee: Glaxo Group Limited
    Inventors: Alessandra Gaiba, Susan Roomans, Martin Edward Swarbrick
  • Benzimidazolones which have activity at M1 receptor
    Patent number: 8288413
    Abstract: Compounds of formula (I) and salts are provided: wherein R6 is selected from hydrogen, halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6 alkoxy, C1-6 alkoxy substituted with one or more fluorine atoms, and cyano, and Q is hydrogen or C1-6alkyl. The compounds are M1 agonists and are useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.
    Type: Grant
    Filed: September 27, 2006
    Date of Patent: October 16, 2012
    Assignee: Glaxo Group Limited
    Inventors: Brian Budzik, David Gwyn Cooper, Ian Thomson Forbes, Jian Jin, Dongchuan Shi, Paul William Smith, Graham Walker
  • Compounds which have activity at Mreceptor and their uses in medicine
    Patent number: 8288412
    Abstract: Compounds of formula (I) and salts are provided: wherein R5 is selected from halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C1-6 alkoxy, C1-6 alkoxy substituted with one or more fluorine atoms, and cyano; R6 is selected from halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6 alkoxy, C1-6 alkoxy substituted with one or more fluorine atoms, and cyano; and Q is hydrogen or C1-6alkyl. The compounds are M1 agonists and are useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.
    Type: Grant
    Filed: September 27, 2006
    Date of Patent: October 16, 2012
    Assignee: Glaxo Group Limited
    Inventors: Brian Budzik, David Gwyn Cooper, Ian Thomson Forbes, Vincenzo Garzya, Jian Jin, Dongchuan Shi, Paul William Smith, Graham Walker
  • Piperazine derivative having affinity for the histamine H3 receptor
    Patent number: 8288389
    Abstract: The present invention relates to 1-(1-methylethyl)-4-{[4-(tetrahydro-2H-pyran-4-yloxy)phenyl]carbonyl}piperazine or a pharmaceutically acceptable salt thereof, in particular the hydrochloride salt thereof and crystalline forms of the hydrochloride salt; to processes for the preparation of the compound or its salt; to compositions containing it; and to its use in the treatment or prophylaxis of neurological or psychiatric diseases, such as cognitive impairment, fatigue or a sleep disorder, for example in a mammal such as a human. The compound or a salt thereof has affinity for and is an antagonist and/or inverse agonist of the histamine H3 receptor.
    Type: Grant
    Filed: September 4, 2008
    Date of Patent: October 16, 2012
    Assignee: Glaxo Group Limited
    Inventors: Desmond John Best, Sing Yeung Mak, Barry Sidney Orlek, Geracimos Rassias, Pamela Joan Theobald
  • Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
    Patent number: 8288610
    Abstract: Methods for amplification of nucleic acids in cells are provided. Also provided are cells that contain the nucleic acids.
    Type: Grant
    Filed: February 14, 2006
    Date of Patent: October 16, 2012
    Assignees: The Biological Research Center of the Hungarian Academy of Sciences, Glaxo Group Limited
    Inventors: Gyula Hadlaczky, Aladar A. Szalay